News for Novartis AG (NVSEF)

Matchpoint Therapeutics and Novartis enter a strategic collaboration for innovative oral treatments. Analyst forecasts present a mixed outlook for Novar

On September 30, 2024, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (Trades, Portfolio), executed a significant transaction involving N

Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 Results Release Conference Call and Live Webcast. [Operator Instructions]. The conference is being recorded.

Novartis AG (NYSE:NVS) is a Swiss pharmaceutical leader focused on developing innovative treatments across oncology, immunology, neuroscience, cardiovascular, and renal diseases.

Novartis AG (NYSE:NVS) is a Swiss pharmaceutical company that is one of the largest of its kind.

The following slide deck was published by Novartis AG in conjunction with their 2025 Q2 earnings call.

The report gave a little bit of everything to Fed policymakers who are divided as to whether tariffs will cause a one-time price shock or something more persistent.

Global economic updates including US inflation, China GDP, and European job data, with insights on tariffs, interest rates, and more.

Sales Growth: Up 11% in constant currency for Q2 2025.Core Operating Income: Increased by 21% in constant currency.Core Margin: Improved by 340 basis points to

Jul 17, 2025 / 12:00PM GMTOperator Good morning and good afternoon,, and welcome to the Novartis Q2 2025 Results Release Conference Call and Live Webcast. (Oper

Novartis (NVS) initiates strategic inventory buildup in the U.S. to mitigate tariff impacts, enhancing overall Q2 performance despite a minor share dip.

Shares of Novartis AG (NVS) fell 3.07% in mid-day trading on Jul 17. The stock reached an intraday low of $114.31, before recovering slightly to $114.74, do

US judge denies Novartis' injunction request against MSN Pharmaceuticals selling generic Entresto, citing public interest and lack of harm.

Summary: Novartis (NVS) is anticipated to report a substantial year-over-year EPS growth of 20.3% and a 12.4% revenue increase in its upcoming second-quarte

Novartis faces a significant legal challenge as a federal judge dismisses its attempt to block a generic competitor. Analyst forecasts suggest a modest

MSN Pharmaceuticals gains momentum as Delaware court rules in favor of its generic version of Entresto. Novartis AG (NVS) faces a challenge to maintain

Novartis (NVS) recently encountered a legal setback as it failed to prevent a generic version of its heart failure drug, Entresto, from going to market. A court

PR NewswireROCKVILLE, Md., July 10, 2025 Construct including CT domain demonstrated higher levels of microdystrophin protein, increased muscle force, and i

Novartis (NVS) has entered into a strategic partnership with Sironax, gaining an exclusive option to acquire Sironax's proprietary Brain Delivery Module (BDM) p